121 related articles for article (PubMed ID: 24093426)
1. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.
Kageyama S; Wada H; Muro K; Niwa Y; Ueda S; Miyata H; Takiguchi S; Sugino SH; Miyahara Y; Ikeda H; Imai N; Sato E; Yamada T; Osako M; Ohnishi M; Harada N; Hishida T; Doki Y; Shiku H
J Transl Med; 2013 Oct; 11():246. PubMed ID: 24093426
[TBL] [Abstract][Full Text] [Related]
2. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.
Ishikawa T; Kageyama S; Miyahara Y; Okayama T; Kokura S; Wang L; Sato E; Yagita H; Itoh Y; Shiku H
Cancer Immunol Immunother; 2021 Nov; 70(11):3081-3091. PubMed ID: 33751208
[TBL] [Abstract][Full Text] [Related]
3. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
Tsuji K; Hamada T; Uenaka A; Wada H; Sato E; Isobe M; Asagoe K; Yamasaki O; Shiku H; Ritter G; Murphy R; Hoffman EW; Old LJ; Nakayama E; Iwatsuki K
Cancer Immunol Immunother; 2008 Oct; 57(10):1429-37. PubMed ID: 18311489
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy.
Nagata Y; Kageyama S; Ishikawa T; Kokura S; Okayama T; Abe T; Murakami M; Otsuka K; Ariyoshi T; Kojima T; Taniguchi K; Kobayashi S; Shimada H; Yajima S; Suzuki T; Hirano S; Tsuchikawa T; Shichinohe T; Ueda S; Kanetaka K; Yoneda A; Wada H; Doki Y; Yamaue H; Katsuda M; Ohi M; Yasuda H; Kondo K; Kataoka M; Kodera Y; Koike M; Shiraishi T; Miyahara Y; Goshima N; Fukuda E; Yamaguchi K; Sato E; Ikeda H; Yamada T; Osako M; Hirai K; Miyamoto H; Watanabe T; Shiku H
Cancer Immunol Immunother; 2022 Nov; 71(11):2743-2755. PubMed ID: 35429246
[TBL] [Abstract][Full Text] [Related]
5. NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma.
Ueda S; Miyahara Y; Nagata Y; Sato E; Shiraishi T; Harada N; Ikeda H; Shiku H; Kageyama S
Oncotarget; 2018 Nov; 9(89):35997-36011. PubMed ID: 30542513
[TBL] [Abstract][Full Text] [Related]
6. Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.
Nicholaou T; Chen W; Davis ID; Jackson HM; Dimopoulos N; Barrow C; Browning J; Macgregor D; Williams D; Hopkins W; Maraskovsky E; Venhaus R; Pan L; Hoffman EW; Old LJ; Cebon J
Cancer Immunol Immunother; 2011 Nov; 60(11):1625-37. PubMed ID: 21698545
[TBL] [Abstract][Full Text] [Related]
7. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
Pavlick A; Blazquez AB; Meseck M; Lattanzi M; Ott PA; Marron TU; Holman RM; Mandeli J; Salazar AM; McClain CB; Gimenez G; Balan S; Gnjatic S; Sabado RL; Bhardwaj N
Cancer Immunol Res; 2020 Jan; 8(1):70-80. PubMed ID: 31699709
[TBL] [Abstract][Full Text] [Related]
8. First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1.
Mahipal A; Ejadi S; Gnjatic S; Kim-Schulze S; Lu H; Ter Meulen JH; Kenney R; Odunsi K
Cancer Immunol Immunother; 2019 Jul; 68(7):1211-1222. PubMed ID: 31069460
[TBL] [Abstract][Full Text] [Related]
9. Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel.
Kageyama S; Kitano S; Hirayama M; Nagata Y; Imai H; Shiraishi T; Akiyoshi K; Scott AM; Murphy R; Hoffman EW; Old LJ; Katayama N; Shiku H
Cancer Sci; 2008 Mar; 99(3):601-7. PubMed ID: 18081877
[TBL] [Abstract][Full Text] [Related]
10. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.
Davis ID; Chen W; Jackson H; Parente P; Shackleton M; Hopkins W; Chen Q; Dimopoulos N; Luke T; Murphy R; Scott AM; Maraskovsky E; McArthur G; MacGregor D; Sturrock S; Tai TY; Green S; Cuthbertson A; Maher D; Miloradovic L; Mitchell SV; Ritter G; Jungbluth AA; Chen YT; Gnjatic S; Hoffman EW; Old LJ; Cebon JS
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10697-702. PubMed ID: 15252201
[TBL] [Abstract][Full Text] [Related]
11. Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma.
Klein O; Davis ID; McArthur GA; Chen L; Haydon A; Parente P; Dimopoulos N; Jackson H; Xiao K; Maraskovsky E; Hopkins W; Stan R; Chen W; Cebon J
Cancer Immunol Immunother; 2015 Apr; 64(4):507-18. PubMed ID: 25662405
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.
Valmori D; Souleimanian NE; Tosello V; Bhardwaj N; Adams S; O'Neill D; Pavlick A; Escalon JB; Cruz CM; Angiulli A; Angiulli F; Mears G; Vogel SM; Pan L; Jungbluth AA; Hoffmann EW; Venhaus R; Ritter G; Old LJ; Ayyoub M
Proc Natl Acad Sci U S A; 2007 May; 104(21):8947-52. PubMed ID: 17517626
[TBL] [Abstract][Full Text] [Related]
13. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1.
Somaiah N; Chawla SP; Block MS; Morris JC; Do K; Kim JW; Druta M; Sankhala KK; Hwu P; Jones RL; Gnjatic S; Kim-Schulze S; Tuballes K; Yishak M; Lu H; Yakovich A; Ter Meulen J; Chen M; Kenney RT; Bohac C; Pollack SM
Oncoimmunology; 2020 Nov; 9(1):1847846. PubMed ID: 33312760
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer.
Kono K; Mizukami Y; Daigo Y; Takano A; Masuda K; Yoshida K; Tsunoda T; Kawaguchi Y; Nakamura Y; Fujii H
Cancer Sci; 2009 Aug; 100(8):1502-9. PubMed ID: 19459850
[TBL] [Abstract][Full Text] [Related]
15. Multiplex genetic manipulations in Clostridium butyricum and Clostridium sporogenes to secrete recombinant antigen proteins for oral-spore vaccination.
Zhang Y; Bailey TS; Hittmeyer P; Dubois LJ; Theys J; Lambin P
Microb Cell Fact; 2024 Apr; 23(1):119. PubMed ID: 38659027
[TBL] [Abstract][Full Text] [Related]
16. Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study.
Saito T; Kurokawa Y; Fujitani K; Kawabata R; Takeno A; Mikami J; Endo S; Matsuyama J; Akamaru Y; Hirota M; Kishi K; Urakawa S; Yamamoto K; Tanaka K; Takahashi T; Oka M; Wada H; Eguchi H; Doki Y
Br J Cancer; 2024 Apr; 130(7):1157-1165. PubMed ID: 38326601
[TBL] [Abstract][Full Text] [Related]
17. Serum NY-ESO-1 and p53 antibodies as useful tumor markers in gastric cancer.
Kawada J; Saito T; Kurokawa Y; Kawabata R; Takeno A; Takeoka T; Nose Y; Wada H; Eguchi H; Doki Y;
Ann Gastroenterol Surg; 2024 Mar; 8(2):243-250. PubMed ID: 38455491
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of p53 and/or NY-ESO-1 autoantibody induction in patients with gastroenterological cancers.
Hoshino I; Nabeya Y; Takiguchi N; Gunji H; Ishige F; Iwatate Y; Shiratori F; Yajima S; Okada R; Shimada H
Ann Gastroenterol Surg; 2020 May; 4(3):275-282. PubMed ID: 32490341
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.
Krishnadas DK; Shusterman S; Bai F; Diller L; Sullivan JE; Cheerva AC; George RE; Lucas KG
Cancer Immunol Immunother; 2015 Oct; 64(10):1251-60. PubMed ID: 26105625
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination.
Miyauchi K; Tsuchikawa T; Wada M; Abiko T; Kyogoku N; Shichinohe T; Miyahara Y; Kageyama S; Ikeda H; Shiku H; Hirano S
Immunotherapy; 2016 May; 8(5):527-40. PubMed ID: 26888315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
